Portrazza
Product Images NDC 0002-7716

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Portrazza (NDC 0002-7716). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Portrazza 800mg Carton 006 01)

Portrazza (necitumumab) injection 800 mg/50 mL (16 mg/mL) vial label for intravenous infusion, manufactured by Eli Lilly and Company. The label includes storage instructions to refrigerate at 2°–8°C, dosing and preparation notes, and indicates no preservative and no U.S. standard of potency. The package shows the NDC 0002-7716-01 and directs discarding unused portion.*

FDA Label Image

Figure 1 (Portrazza Pi F1 V1)

A line graph depicting overall survival percentage over time since randomization (months) comparing two treatment groups: Portrazza combined with gemcitabine and cisplatin versus gemcitabine and cisplatin alone. The graph includes the number of patients at risk at various time points for each group, indicating survival trends over approximately 38 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.